Adam Feuerstein

Adam Feuerstein is an American blogger and columnist covering the biotechnology sector.

Education

Adam Feuerstein completed a bachelor's degree in political science at Emory University.[1]

Career

Feuerstein covered business, technology, and commercial real estate for the San Francisco Business Times and the Atlanta Business Chronicle as an assistant managing editor.[1][2] He later wrote about business software for Upside.com. In March 2001, he joined TheStreet.com. From 2005 to 2006 he worked as a research analyst for a hedge fund before returning to TheStreet. He resigned in May 2017. Feuerstein accepted a position as a national biotechnology columnist at STAT in June 2017.[1]

Feuerstein is known for his style of reporting and his tweets to his large Twitter following.[3][4] He often shares "unabashed" views on Biotech stock and the Food and Drug Administration.[5]

Criticism

Feuerstein has been accused of publishing false or embellished stories in an effort to claim relevance as a journalist and bully companies, most recently in a series of attack stories on a company involved in testing the treatment Leronlimab on severe and critical COVID-19 patients.[6] On July 13th, Cytodyn held an investor conference call[7] where the company declared they fulfill all the requirements for Nasdaq uplisting and the application is ready to be submitted. Same day Feuerstein tweeted "Cytodyn admitted on Monday’s call that it doesn’t meet NASDAQ listing requirements, but announcing things that never happen, like multiple clinical trials and FDA approval submissions, is a deliberate stock-pumping strategy.". The tweet caused anger among shareholders who attended the meeting. Two days later Cytodyn filed Nasdaq uplisting application.[8] Feuerstein has repeatedly been accused of lacking credibility when reporting on clinical trial outcomes given his lack of scientific background academically and professionally. Feuerstein is often the subject of criticism from different parties in the biotechnology sector.[9]

References
  1. Roush, Chris (May 30, 2017). "TheStreet's Feuerstein leaving for STAT". Talking Biz News. Retrieved 2018-11-23.
  2. "Adam Feuerstein Preps for Move to STAT". Cision. June 1, 2017. Retrieved 2018-11-23.
  3. Robbins, Rebecca (May 2, 2016). "Is Adam Feuerstein the most feared man in biotech?". STAT. Retrieved 2018-11-23.
  4. Valleskey, Brianna (November 14, 2014). "How Adam Feuerstein Follows The Biotech Sector". Benzinga. Retrieved 2018-11-23 – via Yahoo.
  5. Schifrin, Matthew (2010-10-01). The Warren Buffetts Next Door: The World's Greatest Investors You've Never Heard Of and What You Can Learn From Them. John Wiley & Sons. p. 88. ISBN 9780470915301.
  6. Growth, Emerging (May 8, 2020). "STAT Reporter Triples Down on CytoDyn (OTCQB: CYDY) Rhetoric with Failed Cyber Bullying Tactics". Emerging Growth. Retrieved 2020-05-08.
  7. "Cydodyn investor conference call". 78449.themediaframe.com. Retrieved 16 July 2020.
  8. "CytoDyn Files Application with Nasdaq for Uplist". CytoDyn Inc. Retrieved 16 July 2020.
  9. Pearlstein, Steven (September 27, 2014). "Northwest Biotherapeutics stock woes highlight the harm of short sales". The Washington Post. Retrieved 2018-11-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.